Bank of New York Mellon Corp Buys New Holdings in Monopar Therapeutics Inc. $MNPR

Key Points

• Bank of New York Mellon acquired 76,942 Monopar Therapeutics shares worth approximately $7.1 million, giving it a 1.15% stake. Other institutions also added shares, but total institutional ownership remains low at 1.83%.
• Analyst sentiment is mostly positive, with Monopar carrying a “Moderate Buy” consensus rating and an average price target of $118.67; targets range from $119 to $130, despite recent downgrades by some firms.
• MNPR traded at $118.55, near its 52-week high of $124.82, after rising 2%. The company slightly beat quarterly EPS expectations, reporting a loss of $0.62 per share versus the projected $0.64 loss.

Bank of New York Mellon Corp purchased a new position in shares of Monopar Therapeutics Inc. (NASDAQ:MNPR - Free Report) during the second quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 76,942 shares of the company's stock, valued at approximately $7,124,000. Bank of New York Mellon Corp owned 1.15% of Monopar Therapeutics as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also added to or reduced their stakes in MNPR. Goldman Sachs Group Inc. bought a new position in shares of Monopar Therapeutics in the 1st quarter worth $673,000. Jane Street Group LLC bought a new stake in shares of Monopar Therapeutics during the first quarter worth about $377,000. Geode Capital Management LLC raised its holdings in shares of Monopar Therapeutics by 99.7% in the 2nd quarter. Geode Capital Management LLC now owns 96,919 shares of the company's stock worth $3,468,000 after acquiring an additional 48,379 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in shares of Monopar Therapeutics by 1,821.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company's stock worth $69,000 after acquiring an additional 1,821 shares during the last quarter. Finally, Rhumbline Advisers bought a new position in Monopar Therapeutics in the 2nd quarter valued at about $209,000. Institutional investors own 1.83% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts have issued reports on MNPR shares. Zacks Research downgraded Monopar Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Thursday, August 13th. UBS Group set a $125.00 price objective on Monopar Therapeutics in a research note on Thursday, July 23rd. Weiss Ratings restated a "sell (d-)" rating on shares of Monopar Therapeutics in a report on Friday, July 17th. Cantor Fitzgerald cut Monopar Therapeutics from an "overweight" rating to a "neutral" rating and lifted their target price for the company from $109.00 to $119.00 in a research report on Thursday, August 13th. Finally, Morgan Stanley reiterated an "overweight" rating and set a $130.00 price target on shares of Monopar Therapeutics in a report on Monday, August 17th. Two investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $118.67.

Insider Buying and Selling

In related news, Director Raymond Anderson sold 3,142 shares of Monopar Therapeutics stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $111.77, for a total value of $351,181.34. Following the sale, the director owned 23,751 shares of the company's stock, valued at approximately $2,654,649.27. The trade was a 11.68% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kim R. Tsuchimoto sold 4,090 shares of the company's stock in a transaction that occurred on Wednesday, August 26th. The shares were sold at an average price of $111.39, for a total value of $455,585.10. Following the completion of the transaction, the director owned 7,396 shares in the company, valued at approximately $823,840.44. The trade was a 35.61% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 9.70% of the stock is owned by corporate insiders.

Monopar Therapeutics Trading Up 2.0%

MNPR stock opened at $118.55 on Friday. The stock's fifty day simple moving average is $109.18 and its two-hundred day simple moving average is $76.76. Monopar Therapeutics Inc. has a 1-year low of $35.01 and a 1-year high of $124.82. The stock has a market cap of $795.47 million, a P/E ratio of -54.63 and a beta of 1.49.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last announced its earnings results on Wednesday, August 12th. The company reported ($0.62) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.64) by $0.02. As a group, analysts forecast that Monopar Therapeutics Inc. will post -2.94 earnings per share for the current fiscal year.

Monopar Therapeutics Company Profile

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company's core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company's pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.

Want to see what other hedge funds are holding MNPR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Monopar Therapeutics Inc. (NASDAQ:MNPR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.